Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
BUSINESS
CEO of Teva-Takeda JV Confident on Handling Both Long-Listed Brands, Generics
Hiroshi Matsumori, CEO and president of a joint venture formed in April between Takeda Pharmaceutical and Teva Holdings, has expressed his confidence about successfully juggling both Takeda’s off-patent brands, called long-listed products, and Teva’s generic drugs under one JV scheme.…
To read the full story
Related Article
- Teva-Takeda JV Eyes Top Spot in Off-Patent Drug Market: CEO
October 11, 2016
- Ex-Pfizer Japan Exec Matsumori to Lead Takeda-Teva JV
April 4, 2016
BUSINESS
- Asahi Kasei Pharma Confident of Hitting FY2030 Group Sales Target: President
December 10, 2025
- Astellas Sees Xtandi Patent Cliff a “Critical Phase,” Steps Up Board Oversight via EPM
December 10, 2025
- PeptiDream Hits Milestone with Asahi Kasei Collaboration
December 10, 2025
- Eisai’s Leqembi Added to China Commercial Insurance Drug List
December 10, 2025
- Drug Makers, Wholesalers See No Major Disruptions after Aomori Quake
December 10, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…